Literature DB >> 22710339

Haematological cancer: The rule of three in AML induction--is cladribine the answer?

Frederick R Appelbaum.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710339     DOI: 10.1038/nrclinonc.2012.98

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Acute myeloid leukemia.

Authors:  Margaret R O'Donnell; Camille N Abboud; Jessica Altman; Frederick R Appelbaum; Steven E Coutre; Lloyd E Damon; James M Foran; Salil Goorha; Lori J Maness; Guido Marcucci; Peter Maslak; Michael M Millenson; Joseph O Moore; Farhad Ravandi; Paul J Shami; B Douglas Smith; Richard M Stone; Stephen A Strickland; Martin S Tallman; Eunice S Wang
Journal:  J Natl Compr Canc Netw       Date:  2011-03       Impact factor: 11.908

2.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

Authors:  Alan K Burnett; Robert K Hills; Donald Milligan; Lars Kjeldsen; Jonathan Kell; Nigel H Russell; John A L Yin; Ann Hunter; Anthony H Goldstone; Keith Wheatley
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

3.  Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

Authors:  Jerzy Holowiecki; Sebastian Grosicki; Sebastian Giebel; Tadeusz Robak; Slawomira Kyrcz-Krzemien; Kazimierz Kuliczkowski; Aleksander B Skotnicki; Andrzej Hellmann; Kazimierz Sulek; Anna Dmoszynska; Janusz Kloczko; Wieslaw W Jedrzejczak; Barbara Zdziarska; Krzysztof Warzocha; Krystyna Zawilska; Mieczyslaw Komarnicki; Marek Kielbinski; Beata Piatkowska-Jakubas; Agnieszka Wierzbowska; Malgorzata Wach; Olga Haus
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

Review 4.  Is a nadir bone marrow required and, if so, what to do with residual disease?

Authors:  Selina M Luger
Journal:  Best Pract Res Clin Haematol       Date:  2011-11-04       Impact factor: 3.020

5.  Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.

Authors:  Shigeki Ohtake; Shuichi Miyawaki; Hiroyuki Fujita; Hitoshi Kiyoi; Katsuji Shinagawa; Noriko Usui; Hirokazu Okumura; Koichi Miyamura; Chiaki Nakaseko; Yasushi Miyazaki; Atsushi Fujieda; Tadashi Nagai; Takahisa Yamane; Masafumi Taniwaki; Masatomo Takahashi; Fumiharu Yagasaki; Yukihiko Kimura; Norio Asou; Hisashi Sakamaki; Hiroshi Handa; Sumihisa Honda; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Blood       Date:  2010-08-06       Impact factor: 22.113

6.  Anthracycline dose intensification in acute myeloid leukemia.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

7.  Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.

Authors:  V Gandhi; E Estey; M J Keating; A Chucrallah; W Plunkett
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

8.  Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.

Authors:  J Holowiecki; S Grosicki; T Robak; S Kyrcz-Krzemien; S Giebel; A Hellmann; A Skotnicki; W W Jedrzejczak; L Konopka; K Kuliczkowski; B Zdziarska; A Dmoszynska; B Marianska; A Pluta; K Zawilska; M Komarnicki; J Kloczko; K Sulek; O Haus; B Stella-Holowiecka; W Baran; B Jakubas; M Paluszewska; A Wierzbowska; M Kielbinski; K Jagoda
Journal:  Leukemia       Date:  2004-05       Impact factor: 11.528

  8 in total
  2 in total

Review 1.  What Is the Optimal Induction Therapy for Younger Fit Patients With AML?

Authors:  Hugo F Fernandez
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

Review 2.  Volasertib for AML: clinical use and patient consideration.

Authors:  Zhonglin Hao; Vamsi Kota
Journal:  Onco Targets Ther       Date:  2015-07-17       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.